Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer

被引：66

作者：

O'Kane, Grainne M. ^{[1
]}

Labbe, Catherine ^{[1
]}

Doherty, Mark K. ^{[1
]}

Young, Kelvin ^{[1
]}

Albaba, Hamzeh ^{[1
]}

Leighl, Natasha B. ^{[1
]}

机构：

[1] Univ Toronto, Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada

来源：

ONCOLOGIST | 2017年 / 22卷 / 01期

关键词：

Lung cancer; Immune-related adverse events; Programmed cell death protein-1; Programmed death ligand-1; Immunotherapy; Toxicities; CHECKPOINT INHIBITORS; METASTATIC MELANOMA; IPILIMUMAB; SAFETY; PEMBROLIZUMAB; THERAPY; NIVOLUMAB; EFFICACY; MULTICENTER; DOCETAXEL;

D O I：

10.1634/theoncologist.2016-0164

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Monoclonal antibodies targeting programmed cell death protein-1 (PD-1) represent a new treatment paradigm in non-small cell lung cancer. Three phase III trials have demonstrated a survival benefit and improved tolerability of nivolumab and pembrolizumab when compared with standard second-line chemotherapy. Nevertheless, the adverse events associated with PD-1 inhibitors are unique; early recognition and treatment are essential. This review summarizes the required monitoring and appropriate management of immune-related adverse events in lung cancer patients receiving these agents.

引用

页码：70 / 80

页数：11

共 68 条

[1]

[Anonymous], 2016, NCCN Clin Pract Guidel Oncol

[2]

[Anonymous], J CLIN ONCOL S

[3] Safety and antitumour activity of durvalumab plus tremelimumab in non-small-cell lung cancer: a multicentre, phase 1b study [J].

Antonia, Scott ;

Goldberg, Sarah B. ;

Balmanoukian, Ani ;

Chaft, Jamie E. ;

Sanborn, Rachel E. ;

Gupta, Ashok ;

Narwal, Rajesh ;

Steele, Keith ;

Gu, Yu ;

Karakunnel, Joyson J. ;

Rizvi, Naiyer A. .

LANCET ONCOLOGY, 2016, 17 (03) :299-308

[4] The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: The Bristol-Myers Squibb experience [J].

Berman, David ;

Korman, Alan ;

Peck, Ronald ;

Feltquate, David ;

Lonberg, Nils ;

Canetta, Renzo .

PHARMACOLOGY & THERAPEUTICS, 2015, 148 :132-153

[5] Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC) [J].

Besse, B. ;

Johnson, M. ;

Jaenne, P. A. ;

Garassino, M. ;

Eberhardt, W. E. E. ;

Peters, S. ;

Toh, C. K. ;

Kurata, T. ;

Li, Z. ;

Kowanetz, M. ;

Mocci, S. ;

Sandler, A. ;

Rizvi, N. A. .

EUROPEAN JOURNAL OF CANCER, 2015, 51 :S717-S718

[6] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[7]

Bostwick A Doran, 2015, J Immunother Cancer, V3, P19, DOI 10.1186/s40425-015-0064-2

[8] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[9]

Bristol-Myers Squibb YERVOY (ipilimumab), SER FAT IMM MED ADV

[10] A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab [J].

Carlos, Giuliana ;

Anforth, Rachael ;

Chou, Shaun ;

Clements, Arthur ;

Fernandez-Penas, Pablo .

MELANOMA RESEARCH, 2015, 25 (03) :265-268

← 1 2 3 4 5 6 7 →